25 XP   0   0   10

Alzamend Neuro Inc
Buy, Hold or Sell?

Let's analyse Alzamend together

PenkeI guess you are interested in Alzamend Neuro Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alzamend Neuro Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alzamend Neuro Inc

I send you an email if I find something interesting about Alzamend Neuro Inc.

Quick analysis of Alzamend (30 sec.)










What can you expect buying and holding a share of Alzamend? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.59
Expected worth in 1 year
$-2.04
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-1.45
Return On Investment
-209.5%

For what price can you sell your share?

Current Price per Share
$0.69
Expected price per share
$0 - $0.862
How sure are you?
50%

1. Valuation of Alzamend (5 min.)




Live pricePrice per Share (EOD)

$0.69

Intrinsic Value Per Share

$-16.65 - $-19.55

Total Value Per Share

$-17.25 - $-20.15

2. Growth of Alzamend (5 min.)




Is Alzamend growing?

Current yearPrevious yearGrowGrow %
How rich?-$4.1m$9.7m-$10.7m-1,093.5%

How much money is Alzamend making?

Current yearPrevious yearGrowGrow %
Making money-$3.1m-$3.8m$761k24.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Alzamend (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#924 / 1016

Most Revenue
#926 / 1016

Most Profit
#358 / 1016

Most Efficient
#371 / 1016

What can you expect buying and holding a share of Alzamend? (5 min.)

Welcome investor! Alzamend's management wants to use your money to grow the business. In return you get a share of Alzamend.

What can you expect buying and holding a share of Alzamend?

First you should know what it really means to hold a share of Alzamend. And how you can make/lose money.

Speculation

The Price per Share of Alzamend is $0.691. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alzamend.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alzamend, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.59. Based on the TTM, the Book Value Change Per Share is $-0.36 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alzamend.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.38-54.6%-0.46-66.1%-0.56-81.4%-0.39-56.4%-0.39-56.4%
Usd Book Value Change Per Share-0.20-29.5%-0.36-52.4%-0.22-32.2%-0.04-5.4%-0.04-5.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.20-29.5%-0.36-52.4%-0.22-32.2%-0.04-5.4%-0.04-5.4%
Usd Price Per Share0.86-0.90-0.94-0.97-0.97-
Price to Earnings Ratio-0.57--0.52--0.45--0.58--0.58-
Price-to-Total Gains Ratio-4.22--2.80--0.67--2.53--2.53-
Price to Book Ratio-1.45--8.06-0.69--1.59--1.59-
Price-to-Total Gains Ratio-4.22--2.80--0.67--2.53--2.53-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.691
Number of shares1447
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.36-0.04
Usd Total Gains Per Share-0.36-0.04
Gains per Quarter (1447 shares)-523.74-53.77
Gains per Year (1447 shares)-2,094.98-215.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2095-21050-215-225
20-4190-42000-430-440
30-6285-62950-645-655
40-8380-83900-860-870
50-10475-104850-1075-1085
60-12570-125800-1290-1300
70-14665-146750-1505-1515
80-16760-167700-1720-1730
90-18855-188650-1936-1945
100-20950-209600-2151-2160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.016.00.00.0%0.016.00.00.0%0.016.00.00.0%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%4.010.02.025.0%4.010.02.025.0%4.010.02.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.016.00.0%0.00.016.00.0%0.00.016.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%4.010.02.025.0%4.010.02.025.0%4.010.02.025.0%

Fundamentals of Alzamend

About Alzamend Neuro Inc

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Fundamental data was last updated by Penke on 2024-04-11 00:22:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Alzamend Neuro Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alzamend earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alzamend to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alzamend Neuro Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y--436.8%+436.8%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Alzamend is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alzamend to the Biotechnology industry mean.
  • -312.3% Return on Assets means that Alzamend generated $-3.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alzamend Neuro Inc:

  • The MRQ is -312.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -199.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-312.3%TTM-199.5%-112.8%
TTM-199.5%YOY-36.3%-163.1%
TTM-199.5%5Y-87.6%-111.9%
5Y-87.6%10Y-87.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-312.3%-13.6%-298.7%
TTM-199.5%-12.9%-186.6%
YOY-36.3%-11.9%-24.4%
5Y-87.6%-14.2%-73.4%
10Y-87.6%-16.2%-71.4%
1.1.3. Return on Equity

Shows how efficient Alzamend is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alzamend to the Biotechnology industry mean.
  • 0.0% Return on Equity means Alzamend generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alzamend Neuro Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-27.1%+27.1%
TTM-27.1%YOY-46.0%+18.9%
TTM-27.1%5Y-56.1%+29.0%
5Y-56.1%10Y-56.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--17.0%+17.0%
TTM-27.1%-16.1%-11.0%
YOY-46.0%-15.4%-30.6%
5Y-56.1%-20.0%-36.1%
10Y-56.1%-21.1%-35.0%

1.2. Operating Efficiency of Alzamend Neuro Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alzamend is operating .

  • Measures how much profit Alzamend makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alzamend to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alzamend Neuro Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y--475.2%+475.2%
10Y--624.7%+624.7%
1.2.2. Operating Ratio

Measures how efficient Alzamend is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y-5.675-5.675
10Y-7.857-7.857

1.3. Liquidity of Alzamend Neuro Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alzamend is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.16 means the company has $0.16 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 0.155. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.821. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.155TTM0.821-0.665
TTM0.821YOY8.411-7.591
TTM0.8215Y5.640-4.819
5Y5.64010Y5.6400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1553.930-3.775
TTM0.8214.251-3.430
YOY8.4115.436+2.975
5Y5.6406.045-0.405
10Y5.6406.363-0.723
1.3.2. Quick Ratio

Measures if Alzamend is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alzamend to the Biotechnology industry mean.
  • A Quick Ratio of 0.07 means the company can pay off $0.07 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 0.074. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.635. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.074TTM0.635-0.561
TTM0.635YOY7.922-7.287
TTM0.6355Y5.111-4.476
5Y5.11110Y5.1110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0743.629-3.555
TTM0.6354.065-3.430
YOY7.9225.397+2.525
5Y5.1115.993-0.882
10Y5.1116.277-1.166

1.4. Solvency of Alzamend Neuro Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alzamend assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alzamend to Biotechnology industry mean.
  • A Debt to Asset Ratio of 5.92 means that Alzamend assets are financed with 591.9% credit (debt) and the remaining percentage (100% - 591.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 5.919. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.794. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ5.919TTM2.794+3.125
TTM2.794YOY0.158+2.635
TTM2.7945Y1.037+1.756
5Y1.03710Y1.0370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.9190.332+5.587
TTM2.7940.334+2.460
YOY0.1580.268-0.110
5Y1.0370.366+0.671
10Y1.0370.390+0.647
1.4.2. Debt to Equity Ratio

Measures if Alzamend is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alzamend to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alzamend Neuro Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.236-0.236
TTM0.236YOY0.204+0.031
TTM0.2365Y0.380-0.144
5Y0.38010Y0.3800.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.381-0.381
TTM0.2360.390-0.154
YOY0.2040.334-0.130
5Y0.3800.434-0.054
10Y0.3800.466-0.086

2. Market Valuation of Alzamend Neuro Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alzamend generates.

  • Above 15 is considered overpriced but always compare Alzamend to the Biotechnology industry mean.
  • A PE ratio of -0.57 means the investor is paying $-0.57 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alzamend Neuro Inc:

  • The EOD is -0.458. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.570. Based on the earnings, the company is expensive. -2
  • The TTM is -0.523. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.458MRQ-0.570+0.112
MRQ-0.570TTM-0.523-0.047
TTM-0.523YOY-0.453-0.070
TTM-0.5235Y-0.576+0.053
5Y-0.57610Y-0.5760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.458-2.315+1.857
MRQ-0.570-2.560+1.990
TTM-0.523-2.664+2.141
YOY-0.453-4.122+3.669
5Y-0.576-6.258+5.682
10Y-0.576-6.108+5.532
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alzamend Neuro Inc:

  • The EOD is -0.600. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.747. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.845. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.600MRQ-0.747+0.147
MRQ-0.747TTM-0.845+0.098
TTM-0.845YOY-0.785-0.060
TTM-0.8455Y-1.000+0.155
5Y-1.00010Y-1.0000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.600-3.067+2.467
MRQ-0.747-3.251+2.504
TTM-0.845-3.545+2.700
YOY-0.785-5.595+4.810
5Y-1.000-8.315+7.315
10Y-1.000-8.708+7.708
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alzamend is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -1.45 means the investor is paying $-1.45 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alzamend Neuro Inc:

  • The EOD is -1.162. Based on the equity, the company is expensive. -2
  • The MRQ is -1.447. Based on the equity, the company is expensive. -2
  • The TTM is -8.063. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.162MRQ-1.447+0.284
MRQ-1.447TTM-8.063+6.616
TTM-8.063YOY0.691-8.754
TTM-8.0635Y-1.594-6.469
5Y-1.59410Y-1.5940.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.1621.905-3.067
MRQ-1.4472.111-3.558
TTM-8.0632.095-10.158
YOY0.6912.836-2.145
5Y-1.5943.443-5.037
10Y-1.5943.794-5.388
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alzamend Neuro Inc.

3.1. Institutions holding Alzamend Neuro Inc

Institutions are holding 5.452% of the shares of Alzamend Neuro Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BB&T Corp.2.33170.00021543271543270
2023-12-31Vanguard Group Inc1.1867078545785450
2023-12-31Geode Capital Management, LLC0.7916052397523970
2023-12-31BlackRock Inc0.6004039740397400
2023-12-31HRT FINANCIAL LLC0.25390.000116806168060
2023-12-31RFG Advisory Group, LLC0.25180.00061666610.006
2023-12-31Renaissance Technologies Corp0.154010190101900
2023-12-31Tower Research Capital LLC0.05010331633160
2023-12-31UBS Group AG0.02880190919090
2023-12-31HARBOR INVESTMENT ADVISORY, LLC0.003020000
2023-12-31Baystate Wealth Management0.001066660
2023-12-31Advisor Group Holdings, Inc.0.001066660
2023-12-31Bank of America Corp0.0007047470
2023-12-31Wells Fargo & Co0.0005035350
2023-12-31Parallel Advisors, LLC0.0005033330
2023-12-31Morgan Stanley - Brokerage Accounts0.0005033330
2023-12-31Bank of New York Mellon Corp000-2691-100
2023-12-31Insight Wealth Strategies, LP000-667-100
2023-09-30Group One Trading, LP000-5062-100
2023-12-31Foundations Investment Advisors, LLC000-1333-100
Total 5.65620.0009374376+347758+92.9%

3.2. Funds holding Alzamend Neuro Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.18670.00017854500
2024-02-29Fidelity Extended Market Index0.36260.000123998-116-0.481
2024-02-29Fidelity Nasdaq Composite Index0.1920.00011270500
2024-02-29Fidelity Total Market Index0.10670706300
2024-02-29Fidelity Series Total Market Index0.08880587800
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.05660.0001374600
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04550.0001300950.1664
2023-12-31Northern Trust Extended Eq Market Idx0.04320286000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04320286000
2024-02-29Spartan Total Market Index Pool E0.03940260500
2023-12-31BNYM Mellon SL Market Completion UC10.0060.0001399-6-1.4815
2023-12-31Northern Trust Wilshire 50000.00470310-1-0.3215
2023-12-31NT US Market Cap Idx Fd - L0.00470310-1-0.3215
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00180.000112100
2024-02-29Spartan Extended Market Index Pool E0.001801161160
2024-02-29Fidelity U.S. Equity Index Ins Trust0.0005032320
2023-12-31BNYM Mellon NSL Mkt Completion Fund Inst0.00010500
Total 2.18430.0007144562+29+0.0%

3.3. Insider Transactions

Insiders are holding 29.635% of the shares of Alzamend Neuro Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-01Milton C Ault IiiBUY3340.91
2024-01-05Milton C Ault IiiBUY50001.02
2023-12-26Milton C Ault IiiBUY5000.9
2023-12-22Milton C Ault IiiBUY2000.92
2023-09-26David J KatzoffBUY35332.85
2023-05-24Milton C Ault IiiBUY12008.85
2023-04-28Stephan JackmanBUY24668.1

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Alzamend Neuro Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.204-0.362+78%-0.222+9%-0.037-82%-0.037-82%
Book Value Per Share---0.595-0.140-77%1.426-142%0.718-183%0.718-183%
Current Ratio--0.1550.821-81%8.411-98%5.640-97%5.640-97%
Debt To Asset Ratio--5.9192.794+112%0.158+3644%1.037+471%1.037+471%
Debt To Equity Ratio---0.236-100%0.204-100%0.380-100%0.380-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.377-0.457+21%-0.562+49%-0.389+3%-0.389+3%
Free Cash Flow Per Share---0.288-0.334+16%-0.304+6%-0.232-19%-0.232-19%
Free Cash Flow To Equity Per Share--0.012-0.258+2301%-0.161+1469%-0.001+109%-0.001+109%
Gross Profit Margin--1.0051.037-3%1.031-3%1.017-1%1.017-1%
Intrinsic Value_10Y_max---19.555--------
Intrinsic Value_10Y_min---16.651--------
Intrinsic Value_1Y_max---1.275--------
Intrinsic Value_1Y_min---1.252--------
Intrinsic Value_3Y_max---4.353--------
Intrinsic Value_3Y_min---4.145--------
Intrinsic Value_5Y_max---8.059--------
Intrinsic Value_5Y_min---7.435--------
Market Cap4744993.350-28%6066714.3406239354.673-3%6425654.888-6%6640449.312-9%6640449.312-9%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio-1.162+20%-1.447-8.063+457%0.691-309%-1.594+10%-1.594+10%
Pe Ratio-0.458+20%-0.570-0.523-8%-0.453-21%-0.576+1%-0.576+1%
Price Per Share0.691-24%0.8600.903-5%0.936-8%0.966-11%0.966-11%
Price To Free Cash Flow Ratio-0.600+20%-0.747-0.845+13%-0.785+5%-1.000+34%-1.000+34%
Price To Total Gains Ratio-3.390+20%-4.219-2.804-34%-0.671-84%-2.531-40%-2.531-40%
Quick Ratio--0.0740.635-88%7.922-99%5.111-99%5.111-99%
Return On Assets---3.123-1.995-36%-0.363-88%-0.876-72%-0.876-72%
Return On Equity----0.2710%-0.4600%-0.5610%-0.5610%
Total Gains Per Share---0.204-0.362+78%-0.222+9%-0.037-82%-0.037-82%
Usd Book Value---4193821.000-985923.500-76%9795053.500-143%4921903.313-185%4921903.313-185%
Usd Book Value Change Per Share---0.204-0.362+78%-0.222+9%-0.037-82%-0.037-82%
Usd Book Value Per Share---0.595-0.140-77%1.426-142%0.718-183%0.718-183%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.377-0.457+21%-0.562+49%-0.389+3%-0.389+3%
Usd Free Cash Flow---2031661.000-2306427.500+14%-2089195.250+3%-1596469.250-21%-1596469.250-21%
Usd Free Cash Flow Per Share---0.288-0.334+16%-0.304+6%-0.232-19%-0.232-19%
Usd Free Cash Flow To Equity Per Share--0.012-0.258+2301%-0.161+1469%-0.001+109%-0.001+109%
Usd Market Cap4744993.350-28%6066714.3406239354.673-3%6425654.888-6%6640449.312-9%6640449.312-9%
Usd Price Per Share0.691-24%0.8600.903-5%0.936-8%0.966-11%0.966-11%
Usd Profit---2662418.000-3100436.250+16%-3861455.250+45%-2665223.938+0%-2665223.938+0%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.204-0.362+78%-0.222+9%-0.037-82%-0.037-82%
 EOD+2 -6MRQTTM+15 -14YOY+16 -135Y+7 -2210Y+7 -22

4.2. Fundamental Score

Let's check the fundamental score of Alzamend Neuro Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.458
Price to Book Ratio (EOD)Between0-1-1.162
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.074
Current Ratio (MRQ)Greater than10.155
Debt to Asset Ratio (MRQ)Less than15.919
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-3.123
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Alzamend Neuro Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.291
Ma 20Greater thanMa 500.897
Ma 50Greater thanMa 1000.941
Ma 100Greater thanMa 2000.950
OpenGreater thanClose0.720
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-01-312023-04-302023-07-312023-10-312024-01-31
Net Debt  -7,3762,235-5,1413,445-1,6951,495-200395195



Latest Balance Sheet

Balance Sheet of 2024-01-31. Currency in USD. All numbers in thousands.

Summary
Total Assets853
Total Liabilities5,046
Total Stockholder Equity-4,194
 As reported
Total Liabilities 5,046
Total Stockholder Equity+ -4,194
Total Assets = 853

Assets

Total Assets853
Total Current Assets594
Long-term Assets259
Total Current Assets
Cash And Cash Equivalents 283
Other Current Assets 311
Total Current Assets  (as reported)594
Total Current Assets  (calculated)594
+/-0
Long-term Assets
Property Plant Equipment 189
Other Assets 0
Long-term Assets  (as reported)259
Long-term Assets  (calculated)189
+/- 70

Liabilities & Shareholders' Equity

Total Current Liabilities3,826
Long-term Liabilities1,220
Total Stockholder Equity-4,194
Total Current Liabilities
Accounts payable 3,826
Other Current Liabilities 3,826
Total Current Liabilities  (as reported)3,826
Total Current Liabilities  (calculated)7,653
+/- 3,826
Long-term Liabilities
Long-term Liabilities  (as reported)1,220
Long-term Liabilities  (calculated)0
+/- 1,220
Total Stockholder Equity
Common Stock1
Retained Earnings -53,169
Other Stockholders Equity 48,974
Total Stockholder Equity (as reported)-4,194
Total Stockholder Equity (calculated)-4,194
+/-0
Other
Capital Stock1
Cash and Short Term Investments 283
Common Stock Shares Outstanding 7,054
Liabilities and Stockholders Equity 853
Net Debt 195
Net Invested Capital -4,264
Net Working Capital -3,233
Short Long Term Debt Total 478



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-01-312023-10-312023-07-312023-04-302023-01-312022-10-312022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312020-07-312020-04-302020-01-312019-10-312019-07-312019-04-30
> Total Assets 
0
0
0
0
1,814
0
0
802
2,913
16,818
14,501
12,429
14,516
12,210
10,425
8,502
5,916
2,628
984
853
8539842,6285,9168,50210,42512,21014,51612,42914,50116,8182,913802001,8140000
   > Total Current Assets 
1,501
2,795
2,795
0
1,814
0
0
802
2,913
16,818
14,501
12,429
14,414
12,115
10,334
8,417
5,836
2,414
782
594
5947822,4145,8368,41710,33412,11514,41412,42914,50116,8182,913802001,81402,7952,7951,501
       Cash And Cash Equivalents 
0
0
0
0
90
0
0
41
1,929
15,618
13,573
11,790
14,064
11,527
9,183
7,376
5,141
1,695
200
283
2832001,6955,1417,3769,18311,52714,06411,79013,57315,6181,9294100900000
       Net Receivables 
285
671
671
0
194
0
0
16
16
16
16
0
0
9
0
0
0
0
0
0
00000090016161616001940671671285
       Other Current Assets 
0
0
0
0
1,529
0
0
745
967
1,183
912
639
350
578
1,152
546
695
718
582
311
3115827186955461,1525783506399121,183967745001,5290000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
103
96
90
85
80
214
202
259
25920221480859096103000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
103
96
90
85
80
214
202
189
18920221480859096103000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000
> Total Liabilities 
0
0
0
0
992
0
0
2,098
900
1,473
1,475
467
1,165
1,029
1,637
2,642
2,870
2,741
3,666
5,046
5,0463,6662,7412,8702,6421,6371,0291,1654671,4751,4739002,098009920000
   > Total Current Liabilities 
1,184
585
585
0
992
0
0
2,098
900
1,473
1,475
467
1,165
1,029
1,637
2,642
2,870
2,741
3,666
3,826
3,8263,6662,7412,8702,6421,6371,0291,1654671,4751,4739002,0980099205855851,184
       Short-term Debt 
0
0
0
0
0
0
0
357
335
340
345
0
0
0
0
0
0
0
0
0
0000000003453403353570000000
       Short Long Term Debt 
0
0
0
0
0
0
0
357
335
340
345
0
0
0
0
0
0
0
0
0
0000000003453403353570000000
       Accounts payable 
1,105
504
504
0
930
0
0
877
504
1,073
1,128
465
1,163
1,029
648
2,642
2,870
2,741
0
3,826
3,82602,7412,8702,6426481,0291,1634651,1281,0735048770093005045041,105
       Other Current Liabilities 
0
81
81
0
63
0
0
864
61
61
2
2
2
1,029
989
2,642
0
2,741
3,666
3,826
3,8263,6662,74102,6429891,02922261618640063081810
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
1,473
465
1,163
1,029
648
2,642
0
0
0
1,220
1,2200002,6426481,0291,1634651,4730000000000
> Total Stockholder Equity
0
0
0
0
822
0
0
-1,296
2,013
15,344
13,025
11,962
13,352
11,182
8,787
5,860
3,046
-113
-2,682
-4,194
-4,194-2,682-1133,0465,8608,78711,18213,35211,96213,02515,3442,013-1,296008220000
   Common Stock
6
6
6
0
6
0
0
6
7
9
9
9
10
10
10
10
10
10
1
1
11101010101010999760060666
   Retained Earnings -53,169-50,506-47,600-44,073-40,767-35,342-32,232-29,194-25,325-22,752-19,152-16,832-15,57600-11,7860-9,258-9,258-7,376
   Accumulated Other Comprehensive Income -478-14,876-14,883-14,883-14,883-14,883-14,883-14,883000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
33,722
49,371
50,652
52,162
57,420
58,287
59,003
0
61,992
0
0
0
00061,992059,00358,28757,42052,16250,65249,37133,72200000000
   Treasury Stock00000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-04-30)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-23
Gross Profit-23-23
 
Operating Income (+$)
Gross Profit-23
Operating Expense-14,870
Operating Income-14,870-14,894
 
Operating Expense (+$)
Research Development7,446
Selling General Administrative6,682
Selling And Marketing Expenses743
Operating Expense14,87014,870
 
Net Interest Income (+$)
Interest Income0
Interest Expense-8
Other Finance Cost-0
Net Interest Income-8
 
Pretax Income (+$)
Operating Income-14,870
Net Interest Income-8
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-14,878-14,863
EBIT - interestExpense = -14,878
-14,878
-14,870
Interest Expense8
Earnings Before Interest and Taxes (EBIT)-14,870-14,870
Earnings Before Interest and Taxes (EBITDA)-14,847
 
After tax Income (+$)
Income Before Tax-14,878
Tax Provision-0
Net Income From Continuing Ops-14,878-14,878
Net Income-14,878
Net Income Applicable To Common Shares-14,878
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses14,870
Total Other Income/Expenses Net-88
 

Technical Analysis of Alzamend
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alzamend. The general trend of Alzamend is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alzamend's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alzamend Neuro Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.74 < 0.85 < 0.862.

The bearish price targets are: .

Tweet this
Alzamend Neuro Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alzamend Neuro Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alzamend Neuro Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alzamend Neuro Inc. The current macd is -0.06565184.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alzamend price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Alzamend. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Alzamend price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Alzamend Neuro Inc Daily Moving Average Convergence/Divergence (MACD) ChartAlzamend Neuro Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alzamend Neuro Inc. The current adx is 27.06.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Alzamend shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Alzamend Neuro Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alzamend Neuro Inc. The current sar is 0.88588086.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Alzamend Neuro Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alzamend Neuro Inc. The current rsi is 30.29. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Alzamend Neuro Inc Daily Relative Strength Index (RSI) ChartAlzamend Neuro Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alzamend Neuro Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alzamend price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Alzamend Neuro Inc Daily Stochastic Oscillator ChartAlzamend Neuro Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alzamend Neuro Inc. The current cci is -193.94740817.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Alzamend Neuro Inc Daily Commodity Channel Index (CCI) ChartAlzamend Neuro Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alzamend Neuro Inc. The current cmo is -52.48548588.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Alzamend Neuro Inc Daily Chande Momentum Oscillator (CMO) ChartAlzamend Neuro Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alzamend Neuro Inc. The current willr is -97.48940333.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Alzamend Neuro Inc Daily Williams %R ChartAlzamend Neuro Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alzamend Neuro Inc.

Alzamend Neuro Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alzamend Neuro Inc. The current atr is 0.07707016.

Alzamend Neuro Inc Daily Average True Range (ATR) ChartAlzamend Neuro Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alzamend Neuro Inc. The current obv is -4,715,101.

Alzamend Neuro Inc Daily On-Balance Volume (OBV) ChartAlzamend Neuro Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alzamend Neuro Inc. The current mfi is 20.89.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Alzamend Neuro Inc Daily Money Flow Index (MFI) ChartAlzamend Neuro Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alzamend Neuro Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Alzamend Neuro Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alzamend Neuro Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.291
Ma 20Greater thanMa 500.897
Ma 50Greater thanMa 1000.941
Ma 100Greater thanMa 2000.950
OpenGreater thanClose0.720
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Alzamend with someone you think should read this too:
  • Are you bullish or bearish on Alzamend? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alzamend? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alzamend Neuro Inc

I send you an email if I find something interesting about Alzamend Neuro Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Alzamend Neuro Inc.

Receive notifications about Alzamend Neuro Inc in your mailbox!